Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03585270 · ClinicalTrials.gov registry record · Phase 3
Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain
A Phase 3 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 409
- Enrollment target
NCT03585270 is a Phase 3 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 409 participants.
The verdict
NCT03585270, a Phase 3 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 409 participants
- Enrollment target
Study Summary
This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.
Interventions
- DRUG Placebo
- DRUG Clazosentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2019-02-03 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03585270
The ClinicalTrials.gov registry entry for NCT03585270 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03585270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03585270 about?
NCT03585270 is a clinical study titled "Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain". This study will evaluate if clazosentan (on top of normal routine medical care) can reduce the risk of developing complications related to cerebral vasospasm and permanent brain damage as compared to normal routine medical care alone.
What is the current status of trial NCT03585270?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 409 participants. The study started on 2019-02-03. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT03585270?
The interventions under investigation include: Placebo (DRUG), Clazosentan (DRUG).
Who is sponsoring clinical trial NCT03585270?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.